Alliqua to List on the NASDAQ Capital Market on January 28, 2014

Alliqua, Inc. (OTCQB: ALQA) (“Alliqua” or the “Company”) has received approval from NASDAQ’s Listing Qualifications Department to list its common stock on the NASDAQ Capital Market. The Company anticipates that its common stock will commence trading on the NASDAQ Capital Market on January 28, 2014 under the same ticker symbol “ALQA”. Until that time, the Company’s common stock will continue to trade on the OTC Markets under the ticker symbol “ALQA”.

“We are extremely honored to have our stock trade on the NASDAQ Capital Market,” stated David Johnson, Chief Executive Officer of Alliqua. “We have made significant progress expanding our product lines, distribution activities and strategic partnerships over the past year. Additionally, we have strengthened our management team and improved our corporate governance across the board. These actions position us well to sustain the positive momentum we have achieved so far in our business. We believe that having our stock trade on NASDAQ will increase our visibility in the market, and ultimately increase our shareholder base.”

About Alliqua, Inc.

Alliqua is a provider of advanced wound care solutions. Through its extensive sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner’s ability to deal with the challenges of healing both chronic and acute wounds.

In addition, Alliqua has both custom manufacturing and transdermal drug delivery capabilities. Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua is also actively developing opportunities to use this same hydrogel technology as a transdermal drug delivery vehicle.

Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress brands, as well as the sorbion sachet S and sorbion sana wound care products. It also has the right to develop and market the advanced wound care products Biovance® and Extracellular Matrix (ECM), as part of its agreement with Celgene Cellular Therapeutics. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.

For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K/A filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Alliqua, Inc.Brian M. Posner, 215-702-8550Chief Financial Officerbposner@alliqua.comorInvestor Relations:Dian Griesel Int'l.Cheryl Schneider, 212-825-3210cschneider@dgicomm.comorPublic Relations:Dian Griesel Int'l.Susan Forman or Laura Radocaj, 212-825-3210sforman@dgicomm.comlradocaj@dgicomm.com

Alliqua, Inc. (NASDAQ:ALQA)
Historical Stock Chart
From Mar 2024 to Apr 2024